Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)
Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research Krankenhaus Nordwest, discusses phase III study findings on perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin vs epirubicin, cisplatin, and fluorouracil or capecitabine for resectable gastric or gastroesophageal junction adenocarcinoma. (Abstract 4004)
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, and Peter H. O’Donnell, MD, of The University of Chicago Medical Center, discuss their study findings on treating advanced urothelial cancer with pembrolizumab, paclitaxel, docetaxel, or vinflunine. (Abstracts 4501 and 4502)
Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.
Viviane Hess, MD, of the University of Basel and University Hospital Basel, discusses a Web-based stress management tool, called STREAM, designed to reduce stress and improve quality of life for newly diagnosed cancer patients, who often lack psychological support. (Abstract LBA10002)
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)
